search
Back to results

Bioequivalence Study of Risperidone 1 mg Tablets of Torrent Pharmaceuticals Limited, India and Risperdal® (Risperidone) 1 mg Tablets of Janssen Pharmaceutical Products, LP, USA, in Healthy Human Adult Subjects, Under Fed Conditions

Primary Purpose

Healthy

Status
Completed
Phase
Phase 1
Locations
India
Study Type
Interventional
Intervention
Risperidone
Sponsored by
Torrent Pharmaceuticals Limited
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional trial for Healthy

Eligibility Criteria

18 Years - 55 Years (Adult)All Sexes

Inclusion Criteria:

  1. Healthy adult subjects of either sex between 18-55 years of age (inclusive) have a body mass index (BMI) between 18 and 27 kg/m2.
  2. Subjects who had no evidence of underlying disease during screening and whose physical examination was performed within 21 days prior to commencement of the study.
  3. Subjects whose screening laboratory values were within normal limits or considered by the Investigator to be of no clinical significance.
  4. Informed consent given in written form according to section 11.3 of the protocol.
  5. Female Subjects:

    • of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the Investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine contraceptive device, (IUD) or abstinence.
    • postmenopausal for at least 1 year.
    • surgically sterile (bilateral tubal ligation, bilateral oophorectomy,or hysterectomy).

Exclusion Criteria:

  1. History or presence of significant:

    • Cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease.
    • Alcohol dependence, alcohol abuse or drug abuse within past one year.
    • Moderate to heavy smoking (>10 cigarettes/day) or consumption of tobacco products.
    • History of difficulty in swallowing tablets.
    • Clinically significant illness within 4 weeks before the start of the study.
    • Asthma, urticaria or other allergic type reactions after taking any medication.
    • Positive urine drug screening, HIV, hepatitis B & C tests.
    • Any history of hypersensitivity to Risperidone.
  2. Participation in any clinical trial within the preceding 12 weeks of study start.
  3. Subjects who had:

    • Systolic blood pressure less than 90 mm of Hg or more than 150 mm of Hg.
    • Diastolic blood pressure less than 60 mm of Hg or more than 94 mm of Hg Minor deviations (2-4 mm Hg) at check-in, if any, were acceptable at the discretion of the physician /Investigator.
    • Pulse rate below 50 /min or above 105 /min.
  4. Female subjects demonstrating a positive pregnancy screen or currently breast-feeding or whose menstruation cycle coincides with the study dates.

Sites / Locations

  • Lotus Labs Pvt. Ltd.

Outcomes

Primary Outcome Measures

Bioequivalence

Secondary Outcome Measures

Full Information

First Posted
July 10, 2009
Last Updated
October 20, 2017
Sponsor
Torrent Pharmaceuticals Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT00939926
Brief Title
Bioequivalence Study of Risperidone 1 mg Tablets of Torrent Pharmaceuticals Limited, India and Risperdal® (Risperidone) 1 mg Tablets of Janssen Pharmaceutical Products, LP, USA, in Healthy Human Adult Subjects, Under Fed Conditions
Official Title
Bioequivalence Study of Risperidone 1 mg Tablets of Torrent Pharmaceuticals Limited., India and Risperdal® (Risperidone) 1 mg Tablets of Janssen Pharmaceutical Products, LP, USA, in Healthy Human Adult Subjects, Under Fed Conditions
Study Type
Interventional

2. Study Status

Record Verification Date
October 2017
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Torrent Pharmaceuticals Limited

4. Oversight

5. Study Description

Brief Summary
Objective: To assess the bioequivalence of Risperidone 1.0 mg tablets of Torrent Pharmaceuticals Limited., India and Risperdal® (Risperidone) 1.0 mg tablets of Janssen Pharmaceutical Products, LP, USA, in healthy human adult subjects, under fed conditions. Study Design: A randomized, open label, two treatment, two period, two sequence, single dose, crossover study, under fed conditions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy

7. Study Design

Study Phase
Phase 1

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Risperidone
Primary Outcome Measure Information:
Title
Bioequivalence

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Eligibility Criteria
Inclusion Criteria: Healthy adult subjects of either sex between 18-55 years of age (inclusive) have a body mass index (BMI) between 18 and 27 kg/m2. Subjects who had no evidence of underlying disease during screening and whose physical examination was performed within 21 days prior to commencement of the study. Subjects whose screening laboratory values were within normal limits or considered by the Investigator to be of no clinical significance. Informed consent given in written form according to section 11.3 of the protocol. Female Subjects: of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the Investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine contraceptive device, (IUD) or abstinence. postmenopausal for at least 1 year. surgically sterile (bilateral tubal ligation, bilateral oophorectomy,or hysterectomy). Exclusion Criteria: History or presence of significant: Cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease. Alcohol dependence, alcohol abuse or drug abuse within past one year. Moderate to heavy smoking (>10 cigarettes/day) or consumption of tobacco products. History of difficulty in swallowing tablets. Clinically significant illness within 4 weeks before the start of the study. Asthma, urticaria or other allergic type reactions after taking any medication. Positive urine drug screening, HIV, hepatitis B & C tests. Any history of hypersensitivity to Risperidone. Participation in any clinical trial within the preceding 12 weeks of study start. Subjects who had: Systolic blood pressure less than 90 mm of Hg or more than 150 mm of Hg. Diastolic blood pressure less than 60 mm of Hg or more than 94 mm of Hg Minor deviations (2-4 mm Hg) at check-in, if any, were acceptable at the discretion of the physician /Investigator. Pulse rate below 50 /min or above 105 /min. Female subjects demonstrating a positive pregnancy screen or currently breast-feeding or whose menstruation cycle coincides with the study dates.
Facility Information:
Facility Name
Lotus Labs Pvt. Ltd.
City
Bangalore
State/Province
Karnataka
Country
India

12. IPD Sharing Statement

Learn more about this trial

Bioequivalence Study of Risperidone 1 mg Tablets of Torrent Pharmaceuticals Limited, India and Risperdal® (Risperidone) 1 mg Tablets of Janssen Pharmaceutical Products, LP, USA, in Healthy Human Adult Subjects, Under Fed Conditions

We'll reach out to this number within 24 hrs